Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
StockNews.AI · 2 hours
AI Summary
Greenwich LifeSciences reported ASCO 2026 abstracts/posters for GLSI-100 in Flamingo-01, showing significant ISR and DTH immune responses across HLA subtypes. The data imply broader immunogenicity beyond HLA-A02 and support recurrence-reduction potential, potentially expanding the patient population and near-term market opportunity; interim results could influence sentiment and valuation.
Sentiment Rationale
Positive ISR/DTH data and suggested expansion of addressable market could lift GLSI valuation; however interim/open-label nature limits certainty and may cap near-term upside.
Trading Thesis
Bullish; if data persist and interim analyses trigger, GLSI could re-rate within 3–6 months.
Market-Moving
- ASCO 2026 data release could reprice GLSI on positive interim results.
- Non-HLA-A02 expansion widens addressable market beyond HLA-A02.
- Interim analysis milestones may spark near-term stock volatility.
Key Facts
- ASCO 2026 abstracts/posters released for GLSI-100 in Flamingo-01.
- Non-HLA-A02 arm shows ISR increase after 4–6 vaccinations.
- Erythema ISR rose 20.2% to 55.3%; Induration 14.9% to 34.6%.
- HLA-A02 and non-HLA-A02 data trend similarly; management cites market potential.
- Interim analysis planned; 500 HLA-A02, 250 non-HLA-A02 arms.
Companies Mentioned
- Greenwich LifeSciences (GLSI): ASCO/ASCO 2026 data; potential expansion beyond HLA-A02; international trials.
Industry News
Industry News: ASCO data release on GLSI-100; signals broader immunogenicity and potential market expansion beyond initial HLA-A02 restriction.